Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Mar 31;79(6):904–913. doi: 10.1097/FJC.0000000000001268

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc.

This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

PMC Copyright notice

FIGURE 6. — Protective effects of dapagliflozin against CI-AKI. Dapagliflozin decreased (A) serum levels and (B) blood urea nitrogen in CI-AKI rats. C, Histological injury scoring at 24 hours after the intravenous injection of iohexol. D, Representative histological image of kidney from representative photomicrographs of tubular cell injury in rat kidney tissue sections. Dapagliflozin significantly attenuated the renal tubular injury at 24 hours after the injection of iohexol. Rats in the DCM and DDCM groups were sequentially injected in the tail vein: indomethacin (10 mg/kg), followed by L-NAME (100 mg/kg) and iohexol (3.5 g/kg) 15 and 30 minutes later. Dapagliflozin was administered to rats in the DDCM group. Original magnification: ×200. H&E staining. *P < 0.05 versus the DCM group; #P < 0.05 versus the D group, n = 5 in each group. The values shown are the mean ± SD. C, control group; D, diabetic rats.